Regenxbio to Trial Duchenne Muscular Dystrophy Gene Therapy
Regenxbio is recruiting for its Phase I/II Affinity Duchenne trial of the RGX-202 gene therapy treatment for Duchenne Muscular Dystrophy.
Regenxbio is recruiting for its Phase I/II Affinity Duchenne trial of the RGX-202 gene therapy treatment for Duchenne Muscular Dystrophy.
Health Union releases a survey that illuminates the perspectives and experiences of people living with spinal muscular atrophy.
RESTEM and JAR of Hope announce a strategic collaboration and launch of a clinical trial to evaluate RESTEM ULS therapy for Duchenne.
CIONIC announces a collaboration with acclaimed designer Yves Behar and his world-renowned multidisciplinary design firm, fuseproject.
Read MoreParent Project Muscular Dystrophy adds the clinic at UPMC Children’s Hospital of Pittsburgh to its Certified Duchenne Care Center Program.
Read MoreFulcrum Therapeutics is using AMRA Medical’s muscle fat infiltration (MFI) as a secondary endpoint in its phase 3 FSHD clinical trial: REACH.
Read MoreParent Project Muscular Dystrophy expands its Certified Duchenne Care Program with the certification of the first clinic in St. Louis.
Read MoreMutations that cause Duchenne muscular dystrophy slow electrical activity in the heart, causing abnormal heart rhythms, a study notes.
Read MoreAMRA Medical publishes results of its Fulcrum-sponsored study highlighting the development and use of a MRI protocol for muscle analysis.
Read MoreParent Project Muscular Dystrophy nominates Duchenne to be part of Recommended Uniform Screening Panel (RUSP) for newborns.
Read MoreICD-10-CM codes for LGMD and several of its subtypes will be fully implemented and ready for use starting this October, MDA reports.
Read MoreAn existing cancer drug could have potential as a treatment for muscular dystrophy, researchers suggest in a new study.
Read MoreParent Project Muscular Dystrophy will host its 2022 Annual Conference in Scottsdale, Arizona, June 23-26.
Read MoreAvidity Biosciences Inc joins in activities to raise awareness for FSHD and highlights preclinical treatment results supporting AOC 1020.
Read MoreThe FSHD Society is holding back-to-back meetings in June in Orlando to help develop treatments for facioscapulohumeral muscular dystrophy.
Read MoreMDA Rivals on Saturday, June 18, aims to support funding for people living with muscular dystrophy, ALS, and related neuromuscular diseases.
Read MoreThe Muscular Dystrophy Association will honor Major League Baseball’s recognition of Lou Gehrig Day at games across the country in June.
Read MoreSOLVE FSHD announces its financial support to FSHD Canada Foundation’s grant funding to facilitate FSHD biomarker research.
Read More